AveXis (NASDAQ:AVXS) received a $110.00 price target from analysts at Canaccord Genuity in a report issued on Wednesday. The firm presently has a “hold” rating on the stock. Canaccord Genuity’s price target would indicate a potential upside of 5.33% from the stock’s current price.
Several other brokerages have also weighed in on AVXS. Zacks Investment Research lowered shares of AveXis from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Chardan Capital restated a “buy” rating on shares of AveXis in a research report on Thursday, November 2nd. Royal Bank of Canada restated a “hold” rating and set a $92.00 target price on shares of AveXis in a research report on Thursday, November 2nd. BidaskClub upgraded shares of AveXis from a “sell” rating to a “hold” rating in a research report on Thursday. Finally, Jefferies Group upped their target price on shares of AveXis to $118.00 and gave the stock a “buy” rating in a research report on Thursday, October 12th. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and thirteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $110.67.
AveXis (NASDAQ:AVXS) opened at $104.43 on Wednesday. AveXis has a one year low of $45.33 and a one year high of $108.27.
In other news, insider Brian K. Kaspar sold 15,000 shares of the stock in a transaction that occurred on Monday, October 9th. The shares were sold at an average price of $101.46, for a total value of $1,521,900.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Sukumar Nagendran sold 1,780 shares of the stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $97.25, for a total transaction of $173,105.00. Following the completion of the sale, the vice president now owns 1,780 shares in the company, valued at $173,105. The disclosure for this sale can be found here. Insiders sold 52,340 shares of company stock worth $5,172,298 over the last quarter. Company insiders own 18.60% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the company. FMR LLC lifted its stake in shares of AveXis by 13.1% during the second quarter. FMR LLC now owns 4,705,433 shares of the company’s stock valued at $386,598,000 after buying an additional 544,475 shares during the period. BlackRock Inc. lifted its stake in shares of AveXis by 34.7% during the second quarter. BlackRock Inc. now owns 2,301,229 shares of the company’s stock valued at $189,069,000 after buying an additional 592,843 shares during the period. Vanguard Group Inc. lifted its stake in shares of AveXis by 31.8% during the second quarter. Vanguard Group Inc. now owns 1,575,205 shares of the company’s stock valued at $129,419,000 after buying an additional 380,396 shares during the period. Janus Henderson Group PLC lifted its stake in shares of AveXis by 52.2% during the third quarter. Janus Henderson Group PLC now owns 1,027,221 shares of the company’s stock valued at $99,363,000 after buying an additional 352,456 shares during the period. Finally, State Street Corp lifted its stake in shares of AveXis by 104.2% during the second quarter. State Street Corp now owns 1,000,001 shares of the company’s stock valued at $82,163,000 after buying an additional 510,189 shares during the period. Institutional investors and hedge funds own 92.88% of the company’s stock.
WARNING: “Canaccord Genuity Reiterates $110.00 Price Target for AveXis (AVXS)” was first posted by American Market News and is owned by of American Market News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/12/21/canaccord-genuity-reiterates-110-00-price-target-for-avexis-avxs.html.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
